Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Aldeyra Therapeutics is a clinical-stage biotechnology company focused on developing therapies for immune-mediated diseases, particularly ocular inflammation and systemic conditions. The company's lead asset, reproxalap, is a reactive aldehyde species (RASP) inhibitor targeting dry eye disease and allergic conjunctivitis, with additional pipeline candidates for systemic autoimmune disorders. With no commercial revenue and negative operating cash flow of approximately $40M annually, the stock trades on clinical trial readouts, regulatory milestones, and cash runway visibility.
Aldeyra operates a classic biotech development model: raise capital through equity offerings and strategic partnerships, fund clinical trials to demonstrate safety and efficacy, obtain FDA approval, then commercialize directly or through partnerships. The RASP inhibition platform targets a novel mechanism (trapping reactive aldehydes) differentiated from anti-inflammatory steroids and immunosuppressants. Pricing power depends on demonstrating superior efficacy or safety versus existing treatments like Restasis, Xiidra, or corticosteroids. The company's value derives from probability-weighted NPV of future product sales, with binary risk around Phase 3 trial outcomes and regulatory decisions. Current burn rate of approximately $10M per quarter requires periodic capital raises, diluting existing shareholders but extending runway to potential commercialization or partnership events.
Phase 3 clinical trial topline data releases for reproxalap in dry eye disease and allergic conjunctivitis (primary endpoints: sign/symptom scores)
FDA regulatory interactions: End-of-Phase 2 meeting feedback, NDA submission timing, Advisory Committee outcomes, approval decisions
Cash position and financing events: equity offerings (dilutive but extend runway), partnership announcements with upfront payments/milestones
Competitive landscape shifts: approval or failure of competing dry eye therapies, new mechanism entrants, patent challenges
Pipeline expansion: IND filings for systemic RASP inhibitors, proof-of-concept data in autoimmune indications beyond ophthalmology
Binary clinical trial risk: Phase 3 failure in reproxalap dry eye program would eliminate 60-80% of company value given pipeline concentration; FDA has historically required two adequate and well-controlled trials for ophthalmic approvals
Regulatory pathway uncertainty: FDA's acceptance of novel RASP inhibition mechanism is unproven; agency may require additional safety studies, longer trial durations, or post-marketing commitments that delay commercialization 1-3 years beyond base case
Reimbursement risk: Payers increasingly scrutinize new ophthalmology drugs; without clear superiority over generic cyclosporine or existing branded therapies, formulary access may require 30-50% price discounts, reducing peak sales potential
Patent cliff exposure: Key reproxalap composition-of-matter patents expire 2032-2035; generic entry shortly after launch would compress commercial window and reduce partnership attractiveness
Established dry eye franchises from Novartis (Xiidra), Sun Pharma (Cequa), and generic Restasis control 70%+ market share with entrenched KOL relationships and reimbursement infrastructure; Aldeyra requires differentiated clinical profile to gain formulary access
Novel mechanism competitors: Oyster Point's Tyrvaya (nasal spray, approved 2021) and Novaliq's NOV03 (perfluorohexyloctane, EU approved) offer differentiation beyond anti-inflammatories; additional TRPM8 agonists and neurostimulation devices in late-stage development fragment market
Big Pharma re-entry risk: Allergan, Bausch + Lomb, and Alcon have exited/deprioritized dry eye but could in-license or acquire competing assets, leveraging superior commercial scale to out-execute Aldeyra's launch
Cash runway risk: With $40M+ annual burn and approximately $80-100M cash position (estimated from current ratio and market cap), Aldeyra likely requires additional financing within 6-9 months; equity raises at current $0.3B market cap are highly dilutive (20-40% per round)
Going concern risk: Auditors may include going concern language if cash runway falls below 12 months without committed financing, triggering technical defaults on vendor contracts and further depressing stock price
Warrant/option overhang: Clinical-stage biotechs typically have 15-25% fully diluted share count from employee options and investor warrants; exercises during positive catalysts dilute existing holders
low - Clinical trial timelines and FDA review processes are largely insulated from GDP fluctuations. However, severe recessions can impact: (1) ability to raise capital as risk appetite for speculative biotech declines, (2) partnership economics as pharma companies reduce M&A/licensing budgets, (3) post-launch uptake if reproxalap is priced as premium therapy without insurance coverage. Dry eye disease affects 16M+ diagnosed Americans with treatment regardless of economic conditions, providing defensive end-market characteristics once commercialized.
Rising interest rates negatively impact Aldeyra through two channels: (1) Valuation compression - clinical-stage biotechs are long-duration assets (cash flows 3-7+ years out) with high sensitivity to discount rates; 100bps rate increase can justify 15-25% lower NPV in DCF models. (2) Financing costs - while current debt is minimal (Debt/Equity 0.32), higher rates increase dilution required in equity raises as investors demand higher returns, and make convertible debt more expensive. Conversely, falling rates expand valuation multiples for pre-revenue growth stories.
Minimal direct credit exposure. Aldeyra does not extend credit to customers (no revenue) and clinical trial expenses are paid upfront or on milestone basis. Indirect exposure: tighter credit conditions reduce availability of venture debt (alternative to equity dilution) and can cause CRO/CMO vendors to demand faster payment terms. Strong current ratio of 2.72 indicates adequate liquidity to meet near-term obligations without credit market access.
growth/speculative - Aldeyra attracts biotech specialists, event-driven hedge funds, and retail investors seeking asymmetric risk/reward around binary clinical catalysts. The stock appeals to investors comfortable with 50-80% downside risk in exchange for potential 200-500% upside if reproxalap achieves approval and commercial success. Not suitable for income investors (no dividend), value investors (no earnings, high P/B of 6.1x), or risk-averse portfolios. Typical holders include biotech-focused funds (Perceptive Advisors, RTW Investments, Boxer Capital) and momentum traders around data readouts.
high - Clinical-stage biotechs exhibit 60-100% annualized volatility with 20-50% single-day moves around trial data releases. Aldeyra's -24.1% one-year return and -7.7% six-month return reflect sector-wide biotech weakness and likely negative sentiment around trial delays or financing concerns. Beta to biotech indices (XBI, IBB) likely 1.5-2.0x. Low float and institutional concentration amplify volatility. Options market typically prices 80-120% implied volatility around known catalyst dates.